Compare GROV & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | RLYB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | 295 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 43.9M |
| IPO Year | N/A | 2021 |
| Metric | GROV | RLYB |
|---|---|---|
| Price | $1.13 | $14.08 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.60 | N/A |
| AVG Volume (30 Days) | 57.3K | ★ 254.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $1.03 | $0.27 |
| 52 Week High | $1.60 | $14.60 |
| Indicator | GROV | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 90.02 |
| Support Level | $1.06 | $0.54 |
| Resistance Level | $1.58 | N/A |
| Average True Range (ATR) | 0.06 | 0.52 |
| MACD | -0.01 | 0.55 |
| Stochastic Oscillator | 22.58 | 83.56 |
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.